

















CLAIMS

1. A composition comprising a salt of a compound selected from the following table:

YDE-001	 Hyp (2S,4R) Gly Gln Glu Gly Leu Ala Gly Pro Lys NH₂
YDE-008	 Hyp (2S,4R) Gly Gln Ala Gly Leu Ala Gly Pro Lys NH₂
YDE-011	 Hyp (2S,4R) Gly Gln Leu Gly Leu Ala Gly Pro Lys NH₂
YDE-015	 Hyp (2S,4R) Gly Gln Asp Val Leu Ala Gly Pro Lys NH₂
YDE-016	 Hyp (2S,4R) Gly Gln Asp Ile Leu Ala Gly Pro Lys NH₂






YDE-023	 Hyp Gly Gln Asp Ser Leu Ala Gly Pro Lys (2<i>S</i>,4<i>R</i>)
YDE-026	 Hyp Gly Gln Homo-Ser Gly Leu Ala Gly Pro Lys (2<i>S</i>,4<i>R</i>)
YDE-038	 (4-hydroxyMe)Pro Gly Gln Leu Gly Leu Ala Gly Pro Lys (2<i>S</i>,4<i>R</i>)
YDE-044	 (4-Me)Pro Gly Gln Leu Gly Leu Ala Gly Pro Lys
YDE-045	 (5-Me)Pro Gly Gln Leu Gly Leu Ala Gly Pro Lys
YDE-048	 Hyp Ala Gln Leu Gly Leu Ala Gly Pro Lys







YDE-049	 Hyp Gly Ala Leu Gly Leu Ala Gly Pro Lys
YDE-054	 Hyp Gly Gln Leu Gly Leu Ala Ala Pro Lys
YDE-057	 D-Hyp (2R,4S) Gly Gln Leu Gly Leu Ala Gly Pro Lys
YDE-058	 D-Hyp (2R,4S) Gly D-Gln D-Leu Gly D-Leu D-Ala Gly D-Pro D-Lys
YDE-060	 D-Hyp (2R,4R) Gly D-Gln D-Leu Gly D-Leu D-Ala Gly D-Pro D-Lys





wherein at least 90% of the compound in the composition is present as the salt; and wherein the salt is selected from a hydrochloride, hydrobromide, sulfate, nitrate, perchlorate, phosphate, formate, acetate, lactate, malate, fumarate, succinate, tartrate, glycolate, salicylate, citrate, methanesulfonate, benzenesulfonate, benzoate, malonate, trichloroacetate, naphthalene-2-sulfonate, oxalate, mandelate, alkylammonium, dialkylammonium, trialkylammonium, tetra-alkyl ammonium, L-arginine, benenthamine, benzathine, betaine, calcium hydroxide, choline, deanol, diethanolamine, diethylamine,

2-(diethylamino)ethanol, ethanolamine, ethylenediamine, N-methylglucamine, hydrabamine, 1H-imidazole, lithium, L-lysine, magnesium, 4-(2-hydroxyethyl)morpholine, piperazine, calcium, magnesium, potassium, 1-(2-hydroxyethyl)pyrrolidine, sodium, triethanolamine, tromethamine, and zinc salt.


2. The composition of claim 1, wherein the compound is selected from the following table:







YDE-001	 Hyp (2S,4R) Gly Gln Glu Gly Leu Ala Gly Pro Lys
YDE-008	 Hyp (2S,4R) Gly Gln Ala Gly Leu Ala Gly Pro Lys
YDE-011	 Hyp (2S,4R) Gly Gln Leu Gly Leu Ala Gly Pro Lys
YDE-015	 Hyp (2S,4R) Gly Gln Asp Val Leu Ala Gly Pro Lys
YDE-016	 Hyp (2S,4R) Gly Gln Asp Ile Leu Ala Gly Pro Lys



YDE-023	 Hyp Gly Gln Asp Ser Leu Ala Gly Pro Lys (2<i>S</i>,4<i>R</i>)
YDE-026	 Hyp Gly Gln Homo-Ser Gly Leu Ala Gly Pro Lys (2<i>S</i>,4<i>R</i>)
YDE-038	 (4-hydroxyMe)Pro Gly Gln Leu Gly Leu Ala Gly Pro Lys (2<i>S</i>,4<i>R</i>)
YDE-044	 (4-Me)Pro Gly Gln Leu Gly Leu Ala Gly Pro Lys
YDE-045	 (5-Me)Pro Gly Gln Leu Gly Leu Ala Gly Pro Lys
YDE-049	 Hyp Gly Ala Leu Gly Leu Ala Gly Pro Lys

YDE-054	 Hyp Gly Gln Leu Gly Leu Ala Ala Pro Lys
YDE-057	 D-Hyp (2R,4S) Gly Gln Leu Gly Leu Ala Gly Pro Lys
YDE-058	 D-Hyp (2R,4S) Gly D-Gln D-Leu Gly D-Leu D-Ala Gly D-Pro D-Lys
YDE-060	 D-Hyp (2R,4R) Gly D-Gln D-Leu Gly D-Leu D-Ala Gly D-Pro D-Lys



3. The composition of claim 2, wherein the compound is selected from the following table:

YDE-001	 Hyp (2S,4R) Gly Gln Glu Gly Leu Ala Gly Pro Lys
---------	---


YDE-008	 Hyp (2S,4R) Gly Gln Ala Gly Leu Ala Gly Pro Lys NH₂
YDE-011	 Hyp (2S,4R) Gly Gln Leu Gly Leu Ala Gly Pro Lys NH₂
YDE-015	 Hyp (2S,4R) Gly Gln Asp Val Leu Ala Gly Pro Lys NH₂
YDE-016	 Hyp (2S,4R) Gly Gln Asp Ile Leu Ala Gly Pro Lys NH₂
YDE-023	 Hyp (2S,4R) Gly Gln Asp Ser Leu Ala Gly Pro Lys NH₂
YDE-026	 Hyp (2S,4R) Gly Gln Homo-Ser Gly Leu Ala Gly Pro Lys NH₂

YDE-038	 (4-hydroxyMe)Pro Gly Gln Leu Gly Leu Ala Gly Pro Lys NH₂ (2S,4R)
YDE-060	 D-Hyp Gly D-Gln D-Leu Gly D-Leu D-Ala Gly D-Pro D-Lys (2R,4R)


4. The composition of claim 3, wherein the compound is selected from the following table:

YDE-011	 Hyp Gly Gln Leu Gly Leu Ala Gly Pro Lys NH₂ (2S,4R)
YDE-060	 D-Hyp Gly D-Gln D-Leu Gly D-Leu D-Ala Gly D-Pro D-Lys (2R,4R)

5. The composition of claim 4, wherein the compound has the structure:






6. The composition of claim 4, wherein the compound has the structure:






7. The composition of claim 1, wherein the compound is selected from the following table:

YDE-044	(4-Me)Pro Gly Gln Leu Gly Leu Ala Gly Pro Lys
YDE-045	(5-Me)Pro Gly Gln Leu Gly Leu Ala Gly Pro Lys
YDE-048	Hyp Ala Gln Leu Gly Leu Ala Gly Pro Lys
YDE-049	Hyp Gly Ala Leu Gly Leu Ala Gly Pro Lys


YDE-054	 Hyp Gly Gln Leu Gly Leu Ala Ala Pro Lys
YDE-057	 D-Hyp Gly Gln Leu Gly Leu Ala Gly Pro Lys (2R,4S)
YDE-058	 D-Hyp Gly D-Gln D-Leu Gly D-Leu D-Ala Gly D-Pro D-Lys (2R,4S)

8. The composition of claim 1, wherein the compound is selected from the following table:




YDE-011	 Hyp Gly Gln Leu Gly Leu Ala Gly Pro Lys (2S,4R)
YDE-048	 Hyp Ala Gln Leu Gly Leu Ala Gly Pro Lys















9. The composition of claim 8, wherein the compound has the structure:




10. Use of a composition comprising a salt of a compound selected from the following table:

YDE-001	 Hyp Gly Gln Glu Gly Leu Ala Gly Pro Lys (2S,4R)
YDE-008	 Hyp Gly Gln Ala Gly Leu Ala Gly Pro Lys (2S,4R)
YDE-011	 Hyp Gly Gln Leu Gly Leu Ala Gly Pro Lys (2S,4R)


YDE-015	 Hyp Gly Gln Asp Val Leu Ala Gly Pro Lys (2<i>S</i>,4<i>R</i>)
YDE-016	 Hyp Gly Gln Asp Ile Leu Ala Gly Pro Lys (2<i>S</i>,4<i>R</i>)
YDE-023	 Hyp Gly Gln Asp Ser Leu Ala Gly Pro Lys (2<i>S</i>,4<i>R</i>)
YDE-026	 Hyp Gly Gln Homo-Ser Gly Leu Ala Gly Pro Lys (2<i>S</i>,4<i>R</i>)
YDE-038	 (4-hydroxyMe)Pro Gly Gln Leu Gly Leu Ala Gly Pro Lys (2<i>S</i>,4<i>R</i>)
YDE-044	 (4-Me)Pro Gly Gln Leu Gly Leu Ala Gly Pro Lys

YDE-045	 (5-Me)Pro Gly Gln Leu Gly Leu Ala Gly Pro Lys
YDE-048	 Hyp Ala Gln Leu Gly Leu Ala Gly Pro Lys
YDE-049	 Hyp Gly Ala Leu Gly Leu Ala Gly Pro Lys
YDE-054	 Hyp Gly Gln Leu Gly Leu Ala Ala Pro Lys
YDE-057	 D-Hyp (2R,4S) Gly Gln Leu Gly Leu Ala Gly Pro Lys
YDE-058	 D-Hyp (2R,4S) Gly D-Gln D-Leu Gly D-Leu D-Ala Gly D-Pro D-Lys





wherein at least 90% of the compound in the composition is present as the salt;
in the manufacture of a medicament for the treatment of an eye disease.







11. The use according to claim 10, wherein the compound has the structure:











12. The use according to claim 10 or 11, wherein the eye disease is dry eye syndrome.

13. An ophthalmic formulation comprising a composition comprising a salt of a compound selected from the following table:

YDE-001	 Hyp Gly Gln Glu Gly Leu Ala Gly Pro Lys (2S,4R)
YDE-008	 Hyp Gly Gln Ala Gly Leu Ala Gly Pro Lys (2S,4R)

YDE-011	 Hyp Gly Gln Leu Gly Leu Ala Gly Pro Lys (2<i>S</i>,4<i>R</i>)
YDE-015	 Hyp Gly Gln Asp Val Leu Ala Gly Pro Lys (2<i>S</i>,4<i>R</i>)
YDE-016	 Hyp Gly Gln Asp Ile Leu Ala Gly Pro Lys (2<i>S</i>,4<i>R</i>)
YDE-023	 Hyp Gly Gln Asp Ser Leu Ala Gly Pro Lys (2<i>S</i>,4<i>R</i>)
YDE-026	 Hyp Gly Gln Homo-Ser Gly Leu Ala Gly Pro Lys (2<i>S</i>,4<i>R</i>)
YDE-038	 (4-hydroxyMe)Pro Gly Gln Leu Gly Leu Ala Gly Pro Lys (2<i>S</i>,4<i>R</i>)


YDE-044	 (4-Me)Pro Gly Gln Leu Gly Leu Ala Gly Pro Lys
YDE-045	 (5-Me)Pro Gly Gln Leu Gly Leu Ala Gly Pro Lys
YDE-048	 Hyp Ala Gln Leu Gly Leu Ala Gly Pro Lys
YDE-049	 Hyp Gly Ala Leu Gly Leu Ala Gly Pro Lys
YDE-054	 Hyp Gly Gln Leu Gly Leu Ala Ala Pro Lys
YDE-057	 D-Hyp (2R,4S) Gly Gln Leu Gly Leu Ala Gly Pro Lys

YDE-058	 D-Hyp (2R,4S) Gly D-Gln D-Leu Gly D-Leu D-Ala Gly D-Pro D-Lys
YDE-060	 D-Hyp (2R,4R) Gly D-Gln D-Leu Gly D-Leu D-Ala Gly D-Pro D-Lys

wherein at least 90% of the compound in the composition is present as the salt; and a pharmaceutically acceptable excipient or carrier.


14. The ophthalmic formulation according to claim 13, wherein the ophthalmic formulation is an eye drop.







15. The ophthalmic formulation according to claim 13 or 14, wherein the compound has the structure:












16. A kit comprising:

(1) a composition comprising a salt of a compound selected from the following table:

YDE-001	 Hyp (2S,4R) Gly Gln Glu Gly Leu Ala Gly Pro Lys
---------	---


YDE-008	 Hyp (2S,4R) Gly Gln Ala Gly Leu Ala Gly Pro Lys NH₂
YDE-011	 Hyp (2S,4R) Gly Gln Leu Gly Leu Ala Gly Pro Lys NH₂
YDE-015	 Hyp (2S,4R) Gly Gln Asp Val Leu Ala Gly Pro Lys NH₂
YDE-016	 Hyp (2S,4R) Gly Gln Asp Ile Leu Ala Gly Pro Lys NH₂
YDE-023	 Hyp (2S,4R) Gly Gln Asp Ser Leu Ala Gly Pro Lys NH₂
YDE-026	 Hyp (2S,4R) Gly Gln Homo-Ser Gly Leu Ala Gly Pro Lys NH₂

YDE-038	 (4-hydroxyMe)Pro Gly Gln Leu Gly Leu Ala Gly Pro Lys (2S,4R)
YDE-044	 (4-Me)Pro Gly Gln Leu Gly Leu Ala Gly Pro Lys
YDE-045	 (5-Me)Pro Gly Gln Leu Gly Leu Ala Gly Pro Lys
YDE-048	 Hyp Ala Gln Leu Gly Leu Ala Gly Pro Lys
YDE-049	 Hyp Gly Ala Leu Gly Leu Ala Gly Pro Lys
YDE-054	 Hyp Gly Gln Leu Gly Leu Ala Ala Pro Lys

YDE-057	 D-Hyp (2R,4S) Gly Gln Leu Gly Leu Ala Gly Pro Lys
YDE-058	 D-Hyp (2R,4S) Gly D-Gln D-Leu Gly D-Leu D-Ala Gly D-Pro D-Lys
YDE-060	 D-Hyp (2R,4R) Gly D-Gln D-Leu Gly D-Leu D-Ala Gly D-Pro D-Lys

wherein at least 90% of the compound in the composition is present as the salt; and
(2) instructions for administration of the composition.

17. The kit according to claim 16, wherein the compound has the structure:



18. A kit comprising an ophthalmic formulation according to any one of claims 13-15; and
instructions for administration of the ophthalmic formulation.